Amgen Reinvests Sales Gains In R&D As Phase II MariTide Readout Approaches

Phase II Studies Failed For IL-2 Mutein, LPAR1 Agonist

 
• By Mandy Jackson
  
Amgen also moved MariTide into a Phase II study in type 2 diabetes (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Scrip